JNJ-678

1383450-81-4

C21H20ClF3N4O3S

DMSO : 65 mg/mL (129.76 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

Others

JNJ-678 (JNJ-53718678) is a novel fusion protein inhibitor in clinical trials for the treatment of respiratory syncytial virus (RSV). IC50 & Target: Fusion protein^[1] In Vitro: JNJ-678 (JNJ-53718678) is a small-molecule respiratory syncytial virus (RSV) fusion inhibitor currently under clinical evaluation in infants hospitalized for RSV infection. JNJ-678 (JNJ-53718678) binds to RSV F protein in its prefusion conformation. JNJ-678 (JNJ-53718678) displays very potent antiviral activity and low cytotoxicity. In addition to its activity against the RSV A2 strain, JNJ-678 (JNJ-53718678) is also highly active against a number of RSV strains from both A and B subtypes. The EC₅₀ in an RSV infection assay using HeLa cells is 460?pM^[1]. In Vivo: Oral treatment of neonatal lambs with JNJ-678 (JNJ-53718678), or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible^[1].